论文部分内容阅读
目的 初步分析互联网+手机视频督导在结核病患者治疗管理中的应用情况.方法 采用前瞻性队列研究的方法,选取深圳市龙华区慢性病防治中心2017年1月1日至2017年4月30日登记治疗的肺结核患者为研究对象,共纳入182例.收集并分析不同特征患者在视频督导系统上传服药的记录情况.结果 182例研究对象,服药次数为7841次,在系统中上传服药信息6000次(76.5％,6000/7841),其中5043次(84.1％,5043/6000)是在发送提醒信息之后上传.服药视频上传率与性别、年龄、民族和治疗种类有关:女性的上传率为79.8％(1839/2305),高于男性的75.2％(4161/5536)(x2=19.34,P＜0.01);20～39岁组上传率为77.2％(5205/6745),高于19岁以下组的71.6％(293/409)(x2=11.55,P=0.003);少数民族患者上传率为72.4％(870/1201),低于汉族的77.3％(5130/6640)(x2=13.15,P＜0.01);复治患者上传率为96.6％(28/29),高于初治患者的76.4％(5972/7812)(x2=6.50,P=0.011).结论 大部分肺结核患者能接受并按要求配合互联网+手机视频督导;需要加强对20～39岁以外人群、男性、少数民族、初治患者督导的培训和指导.“,”Objective To analyze the application of video observed therapy (VOT) for management of tuberculosis patients by internet and mobile phones.Methods In this prospective cohort study,the 182 pulmonary tuberculosis patients who were registered,treated and supervised with VOT in the Shenzhen Longhua Center for Chronic Disease Control from January 1st to April 30th,2017 were enrolled.The medicine record in system of VOT was collected and analyzed.Results The 182 patients in the study had 7841 times of medication administration.The times uploaded in the system were 6000 (76.5％,6000/7841);however,of which 5043 medication times (84.1％,5043/6000) were uploaded after sending reminders.The upload medication rates in VOT system were significantly different between the groups of different gender,age,ethnic and kinds of treatment:The upload medication rate in females was 79.8％ (1839/2305),higher than 75.2％ (4161/5536) of males (x2 =19.34,P＜0.01);the rate in 20-39 years age group was 77.2％ (5205/6745),higher than 71.6％ (293/409) of under 19 years age group (x2 =11.55,P =0.003);the rate in ethnic minority was 72.4％ (870/1201),lower than 77.3％(5130/6640) of ethnic Han (x2 =13.15,P＜0.01);the rate in retreated patients was 96.6％ (28/29),higher than 76.4％ (5972/7812) of initially treated patients (x2 =6.50,P=0.011).Conclsion Most pulmonary tuberculosis patients can accept and comply with VOT supervision as required.Additional training and guidance should be given to the patients not aged 20-39 years,males,ethnic minority patients and the initially treated cases undergoing VOT surveillance.